3D Bioprinting Market Segments And Regional Revenue Forecasts To 2030

3D Bioprinting Industry Overview

The global 3D bioprinting market size was valued at USD 1.7 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 15.8% from 2022 to 2030.

The growth of this market is attributed to a limited number of organ donors, and an increasingly aging population with chronic respiratory disease. Rising R&D investment, technological advancement, and increasing incidence of chronic diseases are other vitally impacting attributes likely to boost market growth during the forecast period. The 3D printing community has responded to the COVID-19 crisis, pledging to support the production of vital medical equipment for hospitals grappling with this pandemic.

Gather more insights about the market drivers, restrains and growth of the Global 3D Bioprinting Market

The recent COVID-19 pandemic has taken hold over the globe, with even the healthcare systems being overburdened. Hence, as a reaction to the rising cases of coronavirus, various 3D Bioprinting communities are responding to the worldwide crises by offering their respective skills to ease the burden on the supply chain and governments. As the cases of COVID-19 are increasing day by day, there has been a shortage of materials for the medical professionals as well as for the general public. One of the biggest issues is the lack of availability of test kits for COVID-19. Hence, various 3D bioprinting companies are manufacturing 3D printers and related software on a large scale. For example, Formlabs company based in Massachusetts, U.S. reportedly manufactures 100,000 nasal swabs for COVID-19 testing each day. Due to the ever-increasing cases of COVID-19, the demand for 3D bioprinters is increasing and the global 3D bioprinting market is slated to showcase exponential growth.

The coronavirus pandemic has also accelerated the development of drug and vaccine testing, as scientists are harnessing new technologies for safety testing in patients after preclinical trials are completed. With the ever-increasing cases of COVID-19, the medical world is also facing a shortage of respirators and ventilators. The 3D bioprinting technology is helping in manufacturing respirators and ventilators to overcome the shortage of these devices.

Recently CLECELL, a 3D bioprinting company, created a respiratory epithelium model using their proprietary 3D printer U-FAB, along with other bioprinting technologies. Respiratory epithelium is a type of tissue that lines most of the respiratory tract. This epithelium acts as a barrier to pathogens and foreign particles. However, it also prevents infection and tissue injury with the help of the mucociliary elevator. Hence, with increasing incidences of demand for this respiratory epithelium model, the market for 3D bioprinting is anticipated to witness growth. Owing to such innovations, the market is expected to witness higher growth during the forecast period.

Many biotherapeutic companies are using 3D bioprinting technology in order to accelerate COVID-19 research. For example, Viscient Biosciences used 3D bioprinting technology to create lung tissue which supports viral infectivity research and helps in searching for effective therapy against SARS-CoV-2, the novel coronavirus which causes COVID-19. The Wyss Institute at Harvard University has designed a fully injection-molded nasopharyngeal swab in collaboration with healthcare, industrial partners, and other research institutes.

3D bioprinting is witnessing demand on a large scale with the increasing spread of the COVID-19 infection. Hence, many pharmaceutical and biopharmaceutical participants are coming forward to help healthcare workers, physicians, and scientists in all possible ways. For example, Stratasys, which is one of the leading manufacturers of 3D printers in America, has manufactured face shields with the help of a 3D bioprinter. Until March 2020, they shipped 100,000 face shields in the U.S.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• Compression Therapy Market - The global compression therapy market size was valued at USD 4.14 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030.
• Wound Debridement Market - The global wound debridement market size was valued at USD 4.45 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030.

Market Share Insights

• November 2019: CELLINK developed the most advanced 3D bioprinting device, Bio X6, as well as Lumen X, which produces vascular structures. Also, Fluicell, a Sweden-based company launched a high-resolution bioprinting technology in both 3D and 2D forms, known as Biopixlar.
• November 2019: BASF GmbH acquired Sculpteo, a 3D printing service provider. This acquisition is anticipated to help BASF to market and establish new industrial 3D printing materials more quickly.

Key Companies profiled:

Some prominent players in the global 3D bioprinting market include

• EnvisionTEC, Inc.
• Organovo Holdings, Inc.
• Inventia Life Science PTY LTD
• Poietis
• Vivax Bio, LLC
• Allevi
• Cyfuse Biomedical K.K.
• 3D Bioprinting Solutions
• Cellink Global
• Regemat 3D S.L.
• Bico group ab,
• Collplant Biotechnologies Ltd.
• Regenhu
• Aspect Biosystems Ltd.
• Advanced Solutions Life Sciences, LLC
• Rokit Healthcare, inc.
• Pandorum Technologies pvt. ltd.
• Foldink Life Science Technologies
• Revotek co., ltd.
• Precise Bio

Order a free sample PDF of the 3D Bioprinting Market Intelligence Study, published by Grand View Research.